DNLI - CIK 0001714899
Denali Therapeutics Inc. (DNLI) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | - |
| FY 2024 | $0.00 | -100.0% |
| FY 2023 | $330.53M | +204.7% |
| FY 2022 | $108.46M | +122.9% |
| FY 2021 | $48.66M | -85.5% |
| FY 2020 | $335.56M | +1174.9% |
| FY 2019 | $26.32M | -79.6% |
| FY 2018 | $129.16M | - |
| FY 2017 |
Denali Therapeutics Inc. (DNLI) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Denali Therapeutics Inc.'s revenue grew from $0.00 to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $0.00 |
| - |
| FY 2016 | $0.00 | - |